Building on the success of previous obesity panels and keynote speakers in Sachs’s Swiss events, they will be holding their first annual BioPharma Obesity Innovation Forum on the 11th January in San Francisco.

We are witnessing a global obesity pandemic. By some estimates, a quarter of the world’s population will be obese by 2025. The obesity/weight loss drug market is the fastest-growing segment in the biopharma industry, with annual sales forecast to rise over $200 billion in the near term. Additionally, over 200 other conditions are associated with obesity. These include cardiometabolic diseases, cancer, inflammatory diseases, infertility, anxiety, depression, and kidney disease. This impacts the reimbursement case.

The BioPharma Obesity Innovation Forum will feature over 7 hours of high-level keynotes, panel discussions, and corporate presentations covering all aspects of the bio-pharma obesity science and market, including drug development and technology, as well as highlighting investment opportunities. Key topics to be covered at the upcoming event include:

• Fireside Chat with Dr. Bei Zhang, Corporate VP & TA Head – Diabetes, Obesity & MASH, Novo Nordisk A/S
• Potential Magnitude of Market & Impact on the Healthcare System Panel
• BioPharma Dealmaking: Building the Pipeline Panel
• Personalized Approaches to Treating Obesity Panel
• Unmet Needs & NextGen Therapeutics Panel
• Obesity, Cardiovascular & Metabolic Diseases Platforms Panel
• Innovation in Digital, Tech & Dx for Obesity, Diabetes & MASH Panel
• Investor Roundtable

If you would like to learn more about the BioPharma Obesity Innovation Forum, click here.